Close Menu

Skyline Diagnostics

The test is based on 13 genes that form a gene signature in the blood of children with Kawasaki disease, and it enables KD to be distinguished from other diseases.

SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.

Technology partners on the study include BioMérieux and SkylineDx, as well as Imperial College London's biomedical electronics unit.

The study's goal is to measure the success rate of SkylineDx's multiple myeloma test in a real-world setting compared to the hospital's current standard.

The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma. 

The company is developing a test to predict the  risk of a melanoma patient's cancer metastasizing in lymph nodes without the need for biopsy.

Invitae said this week that it completed its acquisition of Singular Bio on June 19.

The partners are developing and optimizing an algorithm that assesses the likelihood of a patient's cancer progressing to metastasis.

The companies partnered last month to develop new personalized cancer diagnostics using the Helomics D-Chip bioinformatics platform.

The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.